If apoB is so good, why isn't everybody measuring it? One reason why we need the Netherlands Journal of Medicine!

Netherlands Journal of Medicine

Volumn 63, Issue 6, 2005, Pages 232-235

  Sniderman, Allan D ^a   Rosenbloom, M ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; HUMAN; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL LITERATURE; RISK ASSESSMENT; VASCULAR DISEASE;

APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NETHERLANDS; PERIODICALS;

EID: 21344445239     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Non-fasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002;22:1918-23.
2. Yusuf S, Hawken S, Ounpuu S, et al., on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
3. Elovson J, Chatterton JE, Bell GT, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988;29:1461-73.
4. Lamarche B, Moorjani S, Lupien PJ, et al. Apoprotein A-1 and B levels and the risk of ischemic heart disease during a 5 year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996;94:273-8.
5. Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999;99:2517-22.
6. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
7. Corsetti JP, Zareba W, Moss AJ, Sparks CE. Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis 2004;177:367-73.
8. Pedersen TR, Olsson AG, Faergeman O, et al., for the Scandinavian Simvastatin Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S). Circulation 1998;97:1453-60.
9. Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-84.
10. Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RAH. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in the ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002;105:1162-9.
11. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between the plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004;42:1355-63.
12. Meijssen S, Castro Cabezas M, Twickler TB, Jansen H, Erkelens DW. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J Lipid Res 2000;41:1096-102.
13. Van Lennep JE, Westerveld HT, van Lennep HW, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000;20:2408-13.
14. Packard CJ. Apolipoproteins: the new prognostic indicator? Eur Heart J 2003;suppl 5:D9-D16.
15. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
16. Sniderman AD, Brown BG, Stewart FF, Cianflone K. From familial combined hyperlipidemia to hyperapoB: Unravelling overproduction of heptic apoB lipoproteins. Curr Opin Lipidol 1992;3:137-42.
17. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins, a low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998;32:1648-56.
18. Vakkilainen J, Steiner G, Ansquer JC, et al., for the DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease in the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-7.
19. Sniderman AD, St-Pierre A, Cantin B, Dagenais GR, Depres J-P, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003;91:1173-7.
20. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 2003;361:777-80.
21. Keulen ET, Kruijshoop M, Schaper NC, Hoeks APG, de Bruin TWA. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein 8. Arterioscler Thromb Vasc Biol 2002;22:283-8.
22. Simon A, Chironi G, Gariepy J, Del Pino M, Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 2005;179(2):239-44.
23. Connelly PW, Poapst M, Davignon J, et al. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group. Can J Cardiol 1999;15:409-18.
24. Sniderman AD, Vu H, Cianflone K. The effect of moderate hypertriglyceridemia on the relation or plasma total and LDL apoB levels. Atherosclerosis 1991;89:109-16.
25. Durrington PN, Bolton CN, Hartog H. Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. Clin Chim Acta 1978;82:151-60.
26. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997;17:3542-56.
27. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeniety. J Lipid Res 2002;43:1363-79.
28. Chapman MJ, Paplaud PM, Luc G, et al. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultra-centrifugation. J Lipid Res 1988;29:442-58.
29. Teng B, Thompson GR, Sniderman AD, Forte TM, Krauss RM, Kwiterovich PO. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinaemia, normolipidaemia and familial hypercholesterolaemia. Proc Natl Acad Sci USA 1983;80:6662-6.
30. Sniderman AD, Dagenais GR, Cantin B, Despres JP, Lamarche B. High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol. Am J Cardiol 2001;87:792-3, A8.